Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 416-740-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 weeks, with additional testing for recovery
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well-documented study report equivalent or similar to OECD guideline 408: GLP
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- -
- EC Number:
- 416-740-6
- EC Name:
- -
- Molecular formula:
- Can vary from C30H53O4 (di-C11 rxn product) to C36H65O4 (di-C14 rxn product)
- IUPAC Name:
- Ester reaction products of 1,4-Benzenedicarboxylic acid with C11-14 iso-alcohols, C13-rich
- Details on test material:
- Assumed 100% purity (Lot number 97455). Light yellow liquid with mild odor, stored at room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 120 total (60 males, 60 females) obtained from Charles River Laboratories (Kingston, New York 12484), identified as Albino Rats (Outbred) VAF/Plus® and Crl:CD® (SD)IGS BR. 100 total (50 males, 50 females) were used in the study.
Females were nulliparous and non-pregnant.
Approximately 4 weeks at receipt, approximately 6 weeks at initiation of dosing. Weights at initiation of dosing were mean 205 grams (range 182-233 grams) for males and 160 grams (range 119-175 grams). Individual weights of animals placed on test were within ±20% of the mean weight for each sex.
Animals were acclimated for 14 days. All animals were examined during the acclimation period to confirm suitability for study.
More animals than required for the study were purchased and acclimated. Animals considered unsuitable for the study on the basis of pretest physical examinations were eliminated prior to random selection for group assignment. Disposition of all animals not utilized in the study is maintained in the study file.
Animals considered suitable for study were distributed into 2 groups of 15 animals per sex and 2 groups of 10 animals per sex by a computerized random sort program so that body weight means for each group were comparable. Each rat was identified with a metal ear tag bearing its assigned animal number. The assigned animal number plus the study number comprised the unique animal number for each animal. If the tag was lost, it was replaced. In addition, each cage was provided with a cage card which was color-coded for dose level identification and contained study number and animal number information. Animals were monitored by the technical staff for any conditions requiring possible veterinary care and treated as necessary.
Animals were doubly housed in elevated, stainless steel, wire mesh cages during the first week of the acclimation period and individually housed thereafter. Certified Rodent Diet, No. 5002; (Meal) (PMI Nutrition International, St. Louis, Missouri) was available without restriction. Fresh food was presented weekly. Analysis of each feed lot used during this study was performed by the manufacturer. Results are maintained on file at the Testing Facility. Water was available without restriction via an automated watering system (Elizabethtown Water Company, Westfield, New Jersey). Water analyses are conducted by Elizabethtown Water Company, Westfield, New Jersey (Raritan-East Millstone Plant) to ensure that water meets standards specified under the EPA Federal Safe Drinking Water Act Regulations (40 CFR Part 141). In addition, water samples are collected biannually from representative rooms in the Testing Facility; chemical and microbiological water analyses are conducted on these samples by a subcontract laboratory. Results of all water analyses are maintained on file at the Testing Facility. There were no known contaminants in the feed or water which were expected to interfere with the results of this study.
A twelve hour light/dark cycle controlled via an automatic timer was provided. Temperature was monitored and recorded twice daily and maintained within the specified range to the maximum extent possible. Excursions outside the specified range were not considered to have affected the integrity of the study.
Desired: 18 to 26°C
Actual: 17 to 28°C
Relative humidity was monitored and recorded once daily and maintained within the specified range to the maximum extent possible. Excursions outside the specified range were not considered to have affected the integrity of the study.
Desired: 30 to 70%
Actual: 32 to 78%
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1% methylcellulose (Sigma Chemical Company, Lots 105H0489 and 126H1424)
- Details on oral exposure:
- Animals were dosed by oral gavage once per day with a volume of 5 mL/kg/day. Doses were:
Group I - 0 mg/kg/day
Group II - 50 mg/kg/day
Group III - 500 mg/kg/day
Group IV - 1000 mg/kg/day - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The appropriate amount of test article was weighed out and placed in the beaker into which vehicle was added until the proper volume was reached. Mixture was homogenized for approximately 3 minutes and then stirred with a stir bar/plate for at least 30 minutes or until mixed well.
Doses were prepared once weekly and refrigerated when not in use.
Analyses to determine homogeneity, stability, and concentration of the test and/or control articles with carriers under the conditions of this study were performed by the Testing Facility. Prior to initiation of the study, batches of low-concentration and high- concentration dose solutions were prepared. Three samples each from the top, middle and bottom portion of each mixture were taken for homogeneity analysis. Duplicate samples of the low- and high-concentration dose solutions were assayed for stability 4, 7, and 14 days after preparation (samples for homogeneity assays, evaluated on the day of preparation, were used to establish concentration at time of preparation). All dose levels were assayed weekly for the first four weeks and monthly thereafter (1 sample per concentration was taken and two subsamples were analyzed). - Duration of treatment / exposure:
- Ninety days
- Frequency of treatment:
- Once per day
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 other: mg/kg/day (actual ingested)
- Remarks:
- Doses / Concentrations:
0
Basis:
actual ingested
- Dose / conc.:
- 50 other: mg/kg/day (actual ingested)
- Remarks:
- Doses / Concentrations:
50 mg/kg/day
Basis:
actual ingested
- Dose / conc.:
- 500 other: mg/kg/day (actual ingested)
- Remarks:
- Doses / Concentrations:
500 mg/kg/day
Basis:
actual ingested
- Dose / conc.:
- 1 000 other: mg/kg/day (actual ingested)
- Remarks:
- Doses / Concentrations:
1000 mg/kg/day
Basis:
actual ingested
- No. of animals per sex per dose:
- Primary test group was 10 per sex per dose (80 total)
Recovery was tested with 5 per sex per dose from control and high dose group (20 total) - Control animals:
- yes, concurrent vehicle
- Details on study design:
- This study was conducted for Mobil Business Resources Corporation. It was designed to assess the test substance for potential toxicity when administered orally, via gastric intubation, to Sprague-Dawley CD® rats at dose levels of 50, 500 and 1000 mg/kg/day for a period of at least 90 days and to assess reversiblity of any effects during a four-week recovery period. Data from this study may serve as a basis for classification and labeling of the test article.
This study was designed to meet or exceed the requirements of OECD (Organization for Economic Co-Operation and Development): Guidelines for Testing of Chemicals No. 408: “Subchronic Oral Toxicity - Rodent: 90-day Study” adopted 12 May 1981. In addition, the study was designed in accordance with the Draft Document (March 1997) (May 1996), OECD Guidelines for the Testing of Chemicals, Proposal for Updating Guideline 408, Repeated Dose 90-Day Oral Toxicity Study in Rodents.
This study was conducted in compliance with OECD Principles of Good Laboratory Practices ENV/MC/CI-IEM/(98)17 and EEC Good Laboratory Practices (90/18/EEC). - Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- ---MACROSCOPIC EXAMINATIONS---
Complete macroscopic postmortem examinations were performed on all animals killed at a scheduled sacrifice interval immediately after death. The macroscopic postmortem examination included examination of the external surface and all orifices; the external surfaces of the brain and spinal cord; the organs and tissues of the cranial, thoracic, abdominal and pelvic cavities and neck; and the remainder of the carcass for the presence of macroscopic morphologic abnormalities. Animals were fasted prior to scheduled sacrifices.
Animals which were sacrificed for humane reasons were similarly examined as soon as it was practically possible.
---ORGAN WEIGHTS---
Organs [adrenal glands, aorta, bone and bone marrow (sternum/femur), bone (femur with joint), brain (medulla/pons, cerebrum and cerebellum, optic chiasma), esophagus, eyes, Harderian gland, head, heart, kidneys, large intestine (cecum, colon, rectum), larynx, liver, lungs (with mainstem bronchi), lymph nodes (cervical, mesenteric and submandibular), mammary gland, nerve (sciatic), ovaries, pancreas, Peyer’s patches, pharynx, pituitary gland, prostate gland, salivary glands (submandibular), seminal vesicles, skeletal muscle (Biceps femoris), skin, small intestine (duodenum, ileum,jejunum), spinal cord (cervical, thoracic, lumbar), spleen, stomach, testes with epididymides, thymus, thyroid/parathyroid glands, tongue, trachea, urinary bladder, uterus (body/horns) with cervix, vagina, and tissues with macroscopic findings including tissue masses] were weighed for all animals at the scheduled sacrifice intervals. Prior to weighing, the organs were carefully dissected and properly trimmed to remove adipose and other contiguous tissues in a uniform manner. Organs were weighed as soon as possible after dissection in order to avoid drying. Paired organs were weighed together.
---CLINICAL CHEMISTRY---
-Method of Blood Collection-
Blood for clinical chemistry studies was collected into tubes with no anticoagulant, allowed to clot, and centrifuged to obtain serum.
-Collection Intervals-
Termination: Week 14
Recovery: Week 18
-Number of Animals Bled/lnterval-
Termination: 80 animals (10/sex/group)
Recovery: 20 animals (5/sex/control and high-dose groups)
-Analysis of Blood Samples-
Blood samples were analyzed using a Hitachi 717 Automatic Analyzer (Boehringer Mannheim Corporation) as follows:
Aspartate aminotransferase (Kinetic - Modified IFCC Technique)
Alanine aminotransferase (Kinetic - Modified IFCC Technique)
Alkaline phosphatase (AMP Buffer - Modified Bessey-Lowry-Brock Technique)
Blood urea nitrogen (Modified Urease Technique)
Creatinine (Jaffe Reaction - Kinetic - Alkaline Picrate)
Glucose (Hexokinase Method)
Cholesterol - enzymatic (Cholesterol esterase-cholesterol oxidase Method)
Triglycerides (GPO Triglyceride-lipase Method)
Total protein (Biuret Technique)
Albumin (Bromocresol Green Method)
Globulin (calculated value; total protein - albumin)
Albumin/globulin ratio (calculated value; albumin ÷ globulin)
Total bilirubin (Modified Jendrassik and Grof Method)
Sodium (Ion Selective Electrode)
Potassium (Ion Selective Electrode)
Chloride (Ion Selective Electrode)
Calcium (Cresolphthalein Complexane Method)
Inorganic phosphorus (Phosphomolybdate-UV Method)
Gamma-glutamyl transferase (Kinetic – Szasz, G.)
---HEMATOLOGY---
-Method of Blood Collection-
Blood for hematology studies was collected into tubes containing EDTA anticoagulant. Blood for coagulation studies was collected into tubes containing sodium citrate anticoagulant.
-Collection Intervals-
Termination: Week 14
Recovery: Week 18
-Number of Animals Bled/Interval-
Termination: 80 animals (10/sex/group)
Recovery: 20 animals (5/sex/control and high-dose groups)
-Analysis of Blood Samples-
Blood samples were analyzed using a Teclinicon H-1 Hematology System (Bayer Corporation) as follows:
Hemoglobin concentration
Hematocrit
Erythrocyte count
Platelet count
Mean corpuscular volume
Mean corpuscular hemoglobin
Mean corpuscular hemoglobin concentration
Total leukocyte counts
Differential leukocyte count (When questionable values were obtained, manual differential leukocyte counts and absolute value calculations were performed for verification)
Absolute lymphocytes (calculated value; total WBC x % lymphocyte value ÷ 100)
Absolute segmented neutrophils (calculated value; total WBC x % segmented neutrophil ÷ 100)
Blood samples were analyzed using a Photo-optical clot detection system, COAG-A-MATE® X2 (Organon Teknika Corp) as follows:
Prothrombin time
Activated partial thromboplastin time
Blood samples were also examined for erythrocyte morphology (method not disclosed) - Sacrifice and pathology:
- ---NECROPSY INFORMATION---
-Method of Euthanasia-
Exsanguination following carbon dioxide inhalation.
-Necropsy Intervals-
Termination: Week 14
Recovery; Week 18
-Number of Animals-
Termination: 80 animals (10/sex/group)
Recovery: 19 animals (up to 5/sex/control and high-dose groups)
-Necropsy Order-
A necropsy schedule was established to ensure that approximately equal numbers of males and females were examined on each day of necropsy and that examination of animals of both sexes were performed at similar times of the day throughout the necropsy period. In addition, animals were sacrificed in the following order: one rat each was selected from the control, high-, mid-, and low-dose groups and sacrificed in that order. This sequence was repeated until all the rats were sacrificed.
---HISTOPATHOLOGY---
-TISSUES PRESERVED AND EXAMINED HISTOPATHOLOGICALLY-
The tissues listed above were obtained at the scheduled sacrifice intervals and preserved for all animals. In addition, slides of the indicated tissues were prepared and examined microscopically for the 10 animals per sex from the control and high-dose groups sacrificed at the terminal sacrifice interval. In addition, indicated tissues were examined microscopically for Animal No. 1584 which was sacrificed for humane reasons during the recovery period. Any abnormalities not noted during macroscopic examinations which were seen during histology processing were recorded.
-Preservatives-
All tissues - 10% neutral buffered formalin.
Eyes were placed in glutaraldehyde/paraformaldehyde initially and then retained in 10% formalin. Lungs and urinary bladder were infused with formalin prior to their immersion into a larger volume of the same fixative.
-Processing-
After fixation, the tissues and organs from all animals were routinely processed, embedded in paraffin, cut at a microtome setting of 4- 5 microns, mounted on glass slides, stained with hematoxylin and eosin and examined by light microscopy at Huntingdon Life Sciences, Eye Research Center. The bones were decalcified in formic acid. - Other examinations:
- ---NEUROBEHAVIORAL STUDIES---
Testing was staggered over four sessions with approximately equal numbers of animals per sex per dose group in each session. Noise level in the functional observational battery room was maintained within a level of 55 to 65 decibels by a White Noise Generator, Model MDF 5001 (MDF Products, Inc. Danbury, Connecticut). Temperature, humidity, noise level and illumination of each room were measured and recorded to ensure that variations in environmental conditions were minimal during all evaluations. The functional observational battery was performed for all animals before evaluation of motor activity.
--MOTOR ACTIVITY--
-Method-
Using a modified version of Schulze’s procedures (Schulze, 1990), the locomotor activity of all animals was monitored using an automated Photobeam Activity System (San Diego Instruments, Inc., San Diego, California). Sessions were 60 minutes in length; each session was divided into twelve 5-minute intervals. The time of testing was balanced across treatment groups.
-Frequency-
Pretest: Week 0
Termination: Week 13
Recovery: Week 17
-Temperature-
Temperature was monitored and recorded twice daily, just prior to the first evaluation and just after the last evaluation.
Desired: 18 to 26°C
Actual: 22 to 24 °C
-Relative Humidity-
Relative humidity was monitored and recorded twice daily, just prior to the first evaluation and just after the last evaluation.
Desired: 30 to 70%
Actual: 34 to 78%
-Noise Level-
Noise level was monitored using a Digital Sound Level Meter, Model 840029 (Sper Scientific, Ltd., Scottsdale, Arizona) and recorded twice daily, just prior to the first evaluation and just after the last evaluation.
Desired: 55 to 65 dB
Actual: 57 to 65 dB
-Illumination-
Illumination was monitored using a Photometer I (Quantum Instruments, Inc., Garden City, New York) and recorded twice daily, just prior to the first evaluation and just after the last evaluation.
Desired: <80 footcandles
Actual: <33 footcandles
--FUNCTIONAL OBSERVATIONAL BATTERY
-Method-
A functional observational battery (Moser, 1989) was performed on all animals. Evaluations were performed “blind”, i.e., the observer did not know the identity of the animal’s dose group. Time of testing was counter-balanced across treatment groups.
The following evaluations were performed as part of the functional observational battery:
Home Cage Evaluations: posture, vocalization and palpebral closure.
Handling Evaluations: reactivity to general stimuli (handling); assessment of signs of autonomic function: lacrimation, salivation, altered fur appearance, or red/crusty deposits around eyes.
Open Field Evaluations: arousal level and gait; count of urination and defecation; convulsions, tremors, abnormal movements or behaviors, excessive or repetitive actions; piloerection and exophthalmos.
Reflex Assessments: response to visual (approach response) and auditory (finger snap) stimuli; response to a tail pinch; pupillary function.
Grip Strength (Meyer et al., 1979): Grip strength was measured using a Grip Strength Meter (Columbus Instruments International Corporation, Columbus, Ohio).
Landing Foot Splay: A small dot of paint was applied to each animal’s hindpaws. Each animal was then dropped on to a flat surface from a height of two feet. The distance between the marks left by the hindpaws was measured in centimeters.
Hindlimb Extensor Strength: Animals were held in a vertical position facing the observer with a firm grasp around the thorax. The observer placed one finger against the bottom of each hindpaw and pressed towards the animal. Muscular resistance and pressure exerted by the animals were scored.
Air Righting Ability: Animals were held upside down and dropped from a height of two feet into a container of bedding. The landing position of the animal was recorded.
Body Weight: Animals were removed from their cages and weighed using a Mettler Balance, Model PE4000 (Mettler Instrument Corporation, Hightstown, New Jersey). - Statistics:
- See "Any other information on materials and methods incl. tables" below
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Description (incidence and severity):
- no neoplasias noted
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Dose descriptor:
- NOEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The no observed adverse effect level for oral gavage of 1,4-Benzenedicarboxylic Acid, Di-C11-14-Isoalkyl Ester, C13-Rich is 1000 mg/kg/day. This finding does not warrant the classification of 1,4-Benzenedicarboxylic Acid, Di-C11-14-Isoalkyl Ester, C13-Rich as a specific target organ toxicant under the new Regulation (EC) 1272/2008 on classification, labeling, and packaging of substances and mixtures (CLP) or under the Directive 67/518/EEC for dangerous substances and Directive 1999/45/EC for preparations.
- Executive summary:
1,4-Benzenedicarboxylic Acid, Di-C11-14-Isoalkyl Ester, C13-Rich was administered by oral gavage to 50 male and 50 female Sprague Dawley rats at 0, 50, 500, or 1000 mg/kg for 13 weeks. A subset of animals (5 per sex per dose) from the 0 and 1000 mg/kg/day were monitored for an additional 4 weeks as a recovery group. No adverse effects were noted for physical observations, body weights, food consumption, motor activity levels, functional observational batteries, organ weights or macroscopic and microscopic pathology. At the end of the study, the no observed adverse effect level was determined to be greater than 1000 mg/kg. This finding does not warrant the classification of 1,4-Benzenedicarboxylic Acid, Di-C11-14-Isoalkyl Ester, C13-Rich under the new Regulation (EC) 1272/2008 on classification, labeling, and packaging of substances and mixtures (CLP) or under the Directive 67/518/EEC for dangerous substances and Directive 1999/45/EC for preparations.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.